Abstract
P-025 Synergistic antitumor activity of the BCMA 2+1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have